Literature DB >> 26373763

Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.

Rihyeon Kim1, Jeong Min Lee2,3, Cheong-Il Shin1, Eun Sun Lee4, Jeong Hee Yoon1, Ijin Joo1, Seong Ho Kim1, Inpyeong Hwang1, Joon Koo Han1,5, Byung Ihn Choi4.   

Abstract

OBJECTIVES: To determine the different imaging features of intrahepatic mass-forming cholangiocarcinoma (IMCC) from hepatocellular carcinoma (HCC) on gadoxetic acid-enhanced magnetic resonance imaging (MRI).
METHODS: This retrospective study was institutional review board approved and the requirement for informed consent was waived. Patients who underwent gadoxetic acid-enhanced MRI with histologically confirmed IMCCs (n = 46) or HCCs (n = 58) were included. Imaging features of IMCCs and HCCs on gadoxetic acid-enhanced MRI including T2- and T1-weighted, diffusion weighted images, dynamic study and hepatobiliary phase (HBP) images were analyzed. Univariate and multivariate logistic regression analyses were performed to identify relevant differentiating features between IMCCs and HCCs.
RESULTS: Multivariate analysis revealed heterogeneous T2 signal intensity and a hypointense rim on the HBP as suggestive findings of IMCCs and the wash-in and "portal wash-out" enhancement pattern as well as focal T1 high signal intensity foci as indicative of HCCs (all, p < 0.05). When we combined any three of the above four imaging features, we were able to diagnose IMCCs with 94 % (43/46) sensitivity and 86 % (50/58) specificity.
CONCLUSIONS: Combined interpretation of enhancement characteristics including HBP images, morphologic features, and strict application of the "portal wash-out" pattern helped more accurate discrimination of IMCCs from HCCs. KEY POINTS: • Analysis of enhancement characteristics helped accurate discrimination of IMCCs from HCCs. • Wash-out should be determined on the PVP of gadoxetic acid-enhanced MRI. • A hypointense rim on the HBP was a significant finding of IMCCs.

Entities:  

Keywords:  Cholangiocarcinoma; Gadoxetic acid; Hepatocellular carcinoma; Liver; MRI

Mesh:

Substances:

Year:  2015        PMID: 26373763     DOI: 10.1007/s00330-015-4005-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  43 in total

1.  Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI.

Authors:  Jieun Koh; Yong Eun Chung; Ji Hae Nahm; Ha Yan Kim; Kyung-Sik Kim; Young Nyun Park; Myeong-Jin Kim; Jin-Young Choi
Journal:  Eur Radiol       Date:  2015-05-23       Impact factor: 5.315

2.  Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.

Authors:  Y S Chong; Y K Kim; M W Lee; S H Kim; W J Lee; H C Rhim; S J Lee
Journal:  Clin Radiol       Date:  2012-03-15       Impact factor: 2.350

Review 3.  Hepatobiliary agents and their role in LI-RADS.

Authors:  Thomas A Hope; Kathryn J Fowler; Claude B Sirlin; Eduardo A C Costa; Judy Yee; Benjamin M Yeh; Jay P Heiken
Journal:  Abdom Imaging       Date:  2015-03

4.  Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation.

Authors:  Hyeon Tae Jeong; Myeong-Jin Kim; Yong Eun Chung; Jin Young Choi; Young Nyun Park; Ki Whang Kim
Journal:  AJR Am J Roentgenol       Date:  2013-10       Impact factor: 3.959

5.  Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI.

Authors:  Y Zhang; M Uchida; T Abe; H Nishimura; N Hayabuchi; Y Nakashima
Journal:  J Comput Assist Tomogr       Date:  1999 Sep-Oct       Impact factor: 1.826

6.  Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound.

Authors:  Ramón Vilana; Alejandro Forner; Luis Bianchi; Angeles García-Criado; Jordi Rimola; Carlos Rodríguez de Lope; María Reig; Carmen Ayuso; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

7.  The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.

Authors:  Tae Yeon Jeon; Seong Hyun Kim; Won Jae Lee; Hyo K Lim
Journal:  Abdom Imaging       Date:  2009-04-07

Review 8.  Magnetic resonance imaging of cholangiocarcinoma.

Authors:  Riccardo Manfredi; Brunella Barbaro; Gabriele Masselli; Amorino Vecchioli; Pasquale Marano
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

9.  Peripheral mass-forming cholangiocarcinoma in cirrhotic liver.

Authors:  Su Jin Kim; Jeong Min Lee; Joon Koo Han; Ki Hyun Kim; Jae Young Lee; Byung Ihn Choi
Journal:  AJR Am J Roentgenol       Date:  2007-12       Impact factor: 3.959

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  24 in total

1.  Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size.

Authors:  Ting Ni; Xiao-Sha Shang; Wen-Tao Wang; Xin-Xing Hu; Meng-Su Zeng; Sheng-Xiang Rao
Journal:  Br J Radiol       Date:  2018-06-05       Impact factor: 3.039

Review 2.  Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.

Authors:  Anum Aslam; Amita Kamath; Bradley Spieler; Mark Maschiocchi; Carl F Sabottke; Victoria Chernyak; Sara C Lewis
Journal:  Abdom Radiol (NY)       Date:  2021-04-15

3.  Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging.

Authors:  Dong Ik Cha; Kyung Mi Jang; Seong Hyun Kim; Tae Wook Kang; Kyoung Doo Song
Journal:  Eur Radiol       Date:  2017-04-03       Impact factor: 5.315

4.  Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI.

Authors:  Jiyoung Hwang; Young Kon Kim; Ji Hye Min; Seo-Youn Choi; Woo Kyung Jeong; Seong Sook Hong; Hyun-Joo Kim; Soohyun Ahn; Hyeon Seon Ahn
Journal:  Eur Radiol       Date:  2017-05-12       Impact factor: 5.315

5.  Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease.

Authors:  Si Eun Lee; Chansik An; Shin Hye Hwang; Jin-Young Choi; Kyunghwa Han; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2017-11-13       Impact factor: 5.315

6.  Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma.

Authors:  Chansik An; Hyungjin Rhee; Kyunghwa Han; Jin-Young Choi; Young-Nyun Park; Mi-Suk Park; Myeong-Jin Kim; Sumi Park
Journal:  Eur Radiol       Date:  2016-10-21       Impact factor: 5.315

7.  Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.

Authors:  Shoji Kubo; Hiroji Shinkawa; Yoshinari Asaoka; Tatsuya Ioka; Hiroshi Igaki; Namiki Izumi; Takao Itoi; Michiaki Unno; Masayuki Ohtsuka; Takuji Okusaka; Masumi Kadoya; Masatoshi Kudo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Yoshihiro Sakamoto; Hideyuki Sakurai; Tadatoshi Takayama; Osamu Nakashima; Yasushi Nagata; Etsuro Hatano; Kenichi Harada; Takamichi Murakami; Masakazu Yamamoto
Journal:  Liver Cancer       Date:  2022-02-23       Impact factor: 12.430

8.  Reduction in respiratory motion artefacts on gadoxetate-enhanced MRI after training technicians to apply a simple and more patient-adapted breathing command.

Authors:  Andreas Gutzeit; Simon Matoori; Johannes M Froehlich; Constantin von Weymarn; Carolin Reischauer; Orpheus Kolokythas; Matthias Goyen; Klaus Hergan; Matthias Meissnitzer; Rosemarie Forstner; Jan D Soyka; Aleksis Doert; Dow-Mu Koh
Journal:  Eur Radiol       Date:  2015-11-16       Impact factor: 5.315

9.  Comparison of the effect of region-of-interest methods using gadoxetic acid-enhanced MR imaging with diffusion-weighted imaging on staging hepatic fibrosis.

Authors:  Ying Ding; Shengxiang Rao; Li Yang; Caizhong Chen; Mengsu Zeng
Journal:  Radiol Med       Date:  2016-07-23       Impact factor: 3.469

10.  MRI features of primary rare malignancies of the liver: A report from four university centres.

Authors:  Richard C Semelka; Nadesan Nimojan; Saman Chandana; Miguel Ramalho; Suzanne L Palmer; Danielle DeMulder; Carolina Parada Villavicencio; John Woosley; Bonnie L Garon; Reena C Jha; Frank H Miller; Ersan Altun
Journal:  Eur Radiol       Date:  2017-10-27       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.